190 related articles for article (PubMed ID: 1568457)
1. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.
Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H
Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457
[TBL] [Abstract][Full Text] [Related]
2. [Growth characteristics of a human myeloma cell line transfected with IL-6 cDNA].
Takahashi T; Okuno Y; Ohsugi Y
Rinsho Ketsueki; 1993 Apr; 34(4):423-6. PubMed ID: 8510328
[TBL] [Abstract][Full Text] [Related]
3. Effect of interleukin-6 on the growth of human lung cancer cell line.
Fu J; Zheng J; Fang W; Wu B
Chin Med J (Engl); 1998 Mar; 111(3):265-8. PubMed ID: 10374431
[TBL] [Abstract][Full Text] [Related]
4. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
5. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
Westendorf JJ; Ahmann GJ; Armitage RJ; Spriggs MK; Lust JA; Greipp PR; Katzmann JA; Jelinek DF
J Immunol; 1994 Jan; 152(1):117-28. PubMed ID: 7504707
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of multiple myeloma cell growth].
Simizu S; Konda S
Rinsho Ketsueki; 1993 Apr; 34(4):418-22. PubMed ID: 8510327
[TBL] [Abstract][Full Text] [Related]
7. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
9. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
10. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.
Jernberg H; Pettersson M; Kishimoto T; Nilsson K
Leukemia; 1991 Mar; 5(3):255-65. PubMed ID: 1707469
[TBL] [Abstract][Full Text] [Related]
12. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
14. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines.
Guillaume T; Sekhavat M; Rubinstein DB; Hamdan O; Symann ML
Cancer Res; 1993 Jul; 53(13):3139-44. PubMed ID: 8319222
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 1 autocrine growth system in human multiple myeloma.
Nagata K; Tanaka Y; Oda S; Yamashita U; Eto S
Jpn J Clin Oncol; 1991 Feb; 21(1):22-9. PubMed ID: 2067118
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M
Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
19. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
20. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
Jourdan M; Zhang XG; Portier M; Boiron JM; Bataille R; Klein B
J Immunol; 1991 Dec; 147(12):4402-7. PubMed ID: 1753108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]